Combination therapy with antibody‑drug conjugate RC48 (disitamab vedotin) and zimberelimab (PD‑1 inhibitor) successfully controlled recurrent HER2‑positive breast cancer resistant to trastuzumab emtansine: A case report

Options for later-line therapy are limited for patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer who have exhibited resistance to several systemic treatments. Antibody drug conjugates (ADCs) and immune checkpoint inhibitors are novel approaches for HER2-positive br...

Descripción completa

Detalles Bibliográficos
Autores principales: Fan, Shanmin, He, Lianxiang, Sang, Die
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2023
Materias:
Case-Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10398622/
https://www.ncbi.nlm.nih.gov/pubmed/37545624
http://dx.doi.org/10.3892/ol.2023.13945

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10398622/
https://www.ncbi.nlm.nih.gov/pubmed/37545624
http://dx.doi.org/10.3892/ol.2023.13945

Ejemplares similares